THERAPEUTIC POTENTIAL OF ANTI-NA+/K+-ATPASE ANTIBODIES FOR PARKINSON’S DISEASE

Abstract

Na+/K+-ATPase (NKA) is identified as one of the P-type ATPase and is expressed ubiquitously in all cells. A progressive decline of NKA activity has been well recognized in the ageing process. More importantly, decreased NKA activity is also found in PD patients. Motor symptom of rapid-onset dystonia-Parkinsonism (RDP) and abnormal dopamine metabolites in cerebrospinal fluid exist in the patients harboring genetic mutation of ATP1A3. These findings imply that malfunction of NKA may play an important role in PD pathogenesis. Here, this study aims to: 1). investigate the role of NKA in PD pathogenesis, 2). evaluate the possibility of NKA as a therapeutic target for PD. Both 6-hydroxydopamine (6-OHDA)- and α-Synuclein preformed fibrils (PFF)- induced PD models were employed in this study.